Physician profile
Steven Kong
NPI 1407142052
$65,878.92
in general payments reported to CMS, 2019-2025
29 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22K · 2022: $16K · 2023: $7,214 · 2024: $10K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $10K · Travel and Lodging: $13.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,620.00 |
| Food and Beverage | $10,404.97 |
| Travel and Lodging | $13.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $31,763.42 | 2021-2025 | Vemlidy, Livdelzi, Yeztugo |
| Biohaven Pharmaceuticals, INC. | $12,566.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,676.27 | 2022 | |
| Abbvie INC. | $2,695.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,620.47 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Esperion Therapeutics, INC. | $2,398.25 | 2021-2025 | Nexletol, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,841.57 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $1,064.86 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $825.65 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $603.85 | 2021-2022 | |
| Amarin Pharma, INC. | $567.16 | 2021-2023 | |
| Galderma Laboratories, L.P. | $408.31 | 2024-2025 | Nemluvio |
| Phathom Pharmaceuticals, INC. | $372.98 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $277.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $276.45 | 2021-2023 | Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $275.74 | 2021-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $265.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $262.48 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Ibsa Pharma INC. | $261.67 | 2021-2023 | Licart |
| Vifor Pharma, INC. | $242.63 | 2021-2024 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.01 | 2021-2022 | |
| Intra-Sana Laboratories | $119.96 | 2022 | |
| Ardelyx, INC. | $78.57 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $67.63 | 2022-2023 | Linzess |
| Redhill Biopharma INC. | $52.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.02 | 2024-2025 | Lagevrio |
| Sumitomo Pharma America, INC. | $29.82 | 2024 | Gemtesa |
| Arcutis Biotherapeutics, INC. | $18.57 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.